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There has been increasing interest in the interaction of genetic susceptibility and xenobiotic exposures in cancer etiology. Study of gene-
environment interactions may increase our ability to characterize relatively low population risks if a substantial proportion of the population cancer
burden is attributed to high risk among a smaller group of genetically susceptible members. Further, these studies may provide insight into the
mechanism of carcinogenesis, which can help establish the biologic plausibility of an exposure-cancer relationship. Biologic processes important in
tumorigenesis that exhibit substantial interindividual differences may function as susceptibility factors. Potential examples include polymorphic
enzymes, which activate and detoxify procarcinogens and carcinogens (e.g., certain P450 enzymes, N-acetyltransferase [NAT21, glutathione
S-transferase Ml), and variation in the capacity to repair DNA. Biologic assays are now available to evaluate many of these functions at the DNA and
phenotype level and can be readily incorporated into studies of cancer etiology. - Environ Health Perspect 103(Suppl 8):291-295 (1995)
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Introduction
Numerous environmental carcinogens have
been identified through epidemiologic study
and this knowledge has led directly to
approaches to reduce cancer occurrence.
This approach has been most successful for
relatively potent environmental carcinogens
associated with risks ofabout 2-fold or
greater. Becauseoftheobservational charac-
ter ofepidemiologic studies, interpretation
is problematic when risks are much weaker
than this. There is, however, an increasing
need to characterize such carcinogens as we
attempt to reduce the cancer burden
among the general population. Study of
gene-environment interactions may
increase our ability to characterize relatively
low population risks if a substantial pro-
portion ofthe population cancer burden is
attributed to high risk among a smaller
group ofgenetically susceptible members
exposed to the compound under study. In
addition, these studies may provide insight
into the mechanism of carcinogenesis,
which can help establish the biologic plau-
sibility ofan exposure-cancer relationship.
In this paper, we focus on gene alleles
that are common in the population and
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generally considered polymorphisms (i.e.,
the minor allele frequency is > 0.01); prob-
ably associated with relative risks under 10
and, as such, do not exhibit familial pat-
terns ofinheritance; and may be strongly
dependent on exposure to manifest them-
selves (1,2). In contrast, Li (3) has discussed
single gene mutations which were initially
characterized by studies offamilial cancer,
generally present at lower frequencies, and
associated with very high cancer risk (e.g.,
RBI [retinoblastoma], WTI [Wilm's
tumor], p53 [Li-Fraumeni syndrome], and
APC[adenomatous polyposis coli]) (3).
Potential sources ofsusceptibility for
cancer risk include interindividual varia-
tion in enzymes that activate and detoxify
procarcinogens and carcinogens (e.g.,
Phase I enzymes, which catalyze oxidation,
reduction, and hydrolysis reactions, and
Phase II enzymes, which catalyze conjuga-
tion and synthetic reactions), and repair
DNA. The development of assays to
measure these processes and their initial
application in epidemiologic studies has
been extensively reviewed (4-15). Table 1
includes several examples ofthese processes,
which can be studied at either the DNA
level ifthe genetic basis of the polymor-
phism has been characterized, or at the
phenotypic level using assays that reflect
the function ofeither a single gene product
(e.g., N-acetyltransferase, coded by NAT2)
(4), or ofseveral possible enzymes (e.g.,
DNArepair) (16).
Xenobiotic Chemical
Metabolism
Smoking-associated tumors have provided
a model for the evaluation of potential
genetic risk factors. For example, the
GSTMI gene encodes the cytosolic enzyme
glutathione S-transferase MI, which can
conjugate intermediate metabolites (e.g.,
epoxides) ofseveral compounds, including
polycyclic aromatic hydrocarbons (PAHs)
(17,18) and aflatoxin (19). Deficiency in
this enzyme is caused by inheriting a
homozygous deletion ofthe GSTMI gene
(20-22), which is referred to as the null
Table 1. Selected examples of metabolic and DNA repair processes that can be currently studied, and potentially
relevant exposures.
Susceptibilityfactor Exposure
Metabolism
Phase enzymes
CYPlAl PAHs
CYP1A2 PAHs, heterocyclic/aromatic amines
CYP2E1 Benzene, butadiene, chlorinated solvents, N-nitrosamines
Phase II enzymes
NAT2 Heterocyclic/aromatic amines
GSTMI PAHs, aflatoxin
DNArepair Sunlight, mutagens
PAHs, polychlorinated aromatic hydrocarbons. Datafrom(4-16, 18, 19, 21,24, 41, 45, 47, 48, 52, 59-74).
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genotype and is present in about 30 to 70%
of human populations, depending upon
racial group (20,23-25). Several case-
control studies have demonstrated that this
allele confers increased susceptibility for
lung (26-31) and bladder cancer (32-35);
however, equivocal or negative studies have
also been reported [lung: Shields et al.,
unpublished data; (36); bladder: (25-37)].
Bell et al. (33) demonstrated that the
risk ofbladder cancer associated with heavy
tobacco use (i.e., > 50 pack-years) was 3.5
(95% CI = 1.5-8.0) among subjects with
functional GSTMI genotypes and 5.9
(2.6-13) among subjects with the null
genotype (33). Although the interaction
with genotype was not statistically signifi-
cant, the study suggests that there may be
higher smoking-associated bladder cancer
risks for certain subpopulations. Evidence
supporting the biologic plausibility ofthis
association has recently been provided by a
cross-sectional study that showed that smok-
ers with the null GSTMI genotype had
higher urine mutagenic activity than smok-
erswith functional GSTMI genotypes (38).
An extensive bodyofworkhas indicated
that subjects with the slow N-acetylation
phenotype, which is caused by homozygous
mutations in the NAT2 gene, are at
increased risk for bladder cancer compared
with rapid acetylators, particularly among
populations with exposure to aromatic
amines (4); however, this phenotype does
not appear to be a risk factor for bladder
cancer in populations exposed only to ben-
zidine (39). Vineis et al. (40) provided evi-
dence that the slow N-acetylation phenotype
is associated with a greater tendency to form
4-aminobiphenyl hemoglobin adducts,
which provides biologic support for the
observations on bladder cancer risk.
Biomarkers ofgenetic susceptibility are
being incorporated into studies evaluating
cancer risks associated with exposure to
compounds of uncertain carcinogenicity in
humans. For example, meat cooked at high
temperatures contains heterocyclic amines
(HAAs) that are potent mutagens and ani-
mal carcinogens (41). The cancer risk
posed by exposure to HAAs in the diet
may depend upon the extent to which the
compounds are activated by N-oxidation
(carried out by CYP1A2) and acetylation
(thought to be carried out by NAT2)
(42-46). Interindividual variability in
CYP1A2 activity is known to be partially a
result ofinduction by environmental expo-
sures such as cigarette smoking and dietary
exposure to PAHs; however, there also may
be a genetic component (7). Activity of
NAT2 and CYP1A2 can be characterized
by measuring excreted caffeine metabolites
in urine after caffeine consumption, which
can distinguish between slow and rapid
acetylators and N-oxidizers (47). Recently,
Lang et al. (48) evaluated the risk ofHAA
intake (using preference for meat doneness
as a surrogate) in a case-control study of
colon polyps and cancer. The overall risk
associated with eating well-done meat was
2.1 (adjusted for age and metabolic pheno-
types). Compared with subjects with both
slow N-acetylation and slow CYP1A2
activity (slow/slow) who consumed meat
cooked rare or medium, subjects with
slow/slow phenotypes who ate well-done
meat had a 2.1-fold increased risk, while
subjects with rapid/rapid phenotypes who
ate well-done meat had a 6.4-fold increased
risk. Work is continuing to characterize
food cooking practices as related to HAA
exposure (Sinha et al., unpublished data) to
better quantify the interaction of HAA
exposure, polymorphisms in metabolic
enzymes, and cancer risk.
DNA Repair
Although the relationship between sun
exposure and risk of skin cancer is well
established, it has afforded the opportunity
to test potential genetic susceptibility
markers. Athas et al. (16) developed an
assay that uses cultured lymphocytes to
evaluate the capability ofsubjects to repair
ultraviolet-damaged DNA. Wei et al. (49)
applied this assay to a case-control study of
basal cell carcinoma. Overall, there was a
2.8-fold increased risk for basal cell carci-
noma among individuals with a history of
>6 severe sunburns. Using subjects with
<6 severe sunburns with high DNA repair
capability as the comparison group, sub-
jects with .6 severe sunburns with high
repair capability had a nonsignificant 1.9-
fold increased risk for basal cell carcinoma,
while similarly exposed individuals with
low repair capability had a statistically
significant 5.3-fold increased risk (95%
CI =2.04-12.9 adjusted for age and sex).
The ability to repair DNA damage has
also been evaluated as a potential effect
modifier for smoking-associated tumors.
For example, assays have been developed to
detect the in vitro sensitivity of cultured
peripheral lymphocytes to mutagen-
induced chromosomal aberrations, which
are believed to provide an indirect assess-
ment of DNA-repair capability (12). Hsu
et al. (50) developed an assay that quanti-
fies bleomycin-induced chromatid breakage
using cultured lymphocytes from study
subjects. Recently, Wu et al. (51) used this
assay in a case-control study oflung can-
cer. There was an overall 8.8-fold increased
risk oflung cancer associated with smok-
ing, which was strengthened among the
subgroup ofparticipants who were suscep-
tible for bleomycin-induced chromosomal
damage and weakened among subjects who
were not susceptible. For example, the risk
oflung cancer among smokers who did not
form breaks on chromosome 2 was 4.5
(1.6-12.4) (compared with nonsmokers
who did not form breaks), and 12.8
(4.3-38.7) among smokers who did form
breaks. Similar findings were noted for
chromosomes 4 and 5. This assay has also
been used to study susceptibility for pri-
mary malignancies ofthe upper aerodiges-
tive tract (52) and for second malignancies
ofthe head and neck (53).
Methodologic Issues
The case-control design is very efficient for
examining the interaction ofgenetic suscep-
tibility markers and environmental expo-
sures (54), particularly when high quality
exposure data are available from question-
naires or environmental monitoring. There
is a critical need for more valid and reliable
methods ofobtaining data on dietary, envi-
ronmental, and occupational exposure to
carcinogens by questionnaire [Sinha et al.,
unpublished data; (55,56)], particularly
since there may be subtle exposure/gene
interactions, where particular alleles are
associated with greater risk of cancer at
varying levels of exposure to carcinogens
(31,57). These interactions are likely to be
missed ifadequate attention is not given to
exposure assessment.
Ifthe basis ofobserved interindividual
variation in a potential susceptibility factor
has been characterized at the DNA level, it
can be readily studied using DNA collected
from peripheral blood samples, or poten-
tially from less invasive sources of DNA
(e.g., buccal swabs, which collect small
amounts of exfoliated epithelial cells). If a
susceptibility factor has not been character-
ized at the DNA level, then it is necessary
to use an assay that measures the pheno-
typic expression of that variation. Each
assay has its own logistic demands, and
consideration must be given to the extent to
which disease status may potentially influ-
ence such assays. Regardless ofwhich assay
is used, reliability and accuracy ofassays is
critical to any epidemiologic investigation.
Even small degrees ofgenotype or pheno-
type misclassification may have a substantial
impact on risk estimates, particularly when
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the prevalence of the at-risk allele is either
very low or very high (58).
Summary
Although the relevance of interindividual
variability in metabolism and DNA
repair for cancer risk among the general
population is unclear, several studies
support the concept that variation in these
processes, particularly in combination
with exposure to certain types and levels
of carcinogens, may contribute to the
cancer burden. Evaluating these factors
will be an increasingly important goal for
future studies of cancer etiology. These
studies will have the potential to provide
insight into the mechanism ofcarcinogen-
esis in humans, and may increase our abil-
ity to make better estimates of risk for
particular subpopulations.
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